지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술대회자료
- 저자정보
- 발행연도
- 2021.6
- 수록면
- 209 - 209 (1page)
이용수
초록· 키워드
오류제보하기
Background/Aims
Adjuvant chemotherapy plays important role in the survival outcome of majority of solid tumors.
Delaying adjuvant chemotherapy has been proven to worsen outcomes of many cancers, including colon and breast cancer, but unclear in EOC. Surgical resection leads to accelerated metastatic tumor growth due to shuttling of cells in G0 phase into the cell cycle. The interval between resection and chemotherapy provides opportunity for micrometastases to proliferate. But the impact of time to start adjuvant chemotherapy in EOC is unclear, even though multiple large retrospective data or meta-analysis exists in the literature. The impact of same after HIPEC has not been published so far.
Methods
Prospective study
Manipal Comprehensive Cancer Centre, Bangalore, India. METHODOLOGY:
Optimal cytoreduction done with standard steps of CRS.
In patients who were planned for intraperitoneal chemotherapy (IP), port was inserted at the end of the procedure. For patient who were planned for HIPEC, HIPEC was done by semi open technique at the end of CRS and was based on the institutional protocol (Inj cisplatin 100mg/m2 over 90min at 41.50. Patients received adjuvant chemotherapy on day-care basis after the recovery and IP chemotherapy for IP port group. Time to start adjuvant chemotherapy (from the day of surgery) was calculated for all 3 groups: 42 days was t ... 전체 초록 보기
Adjuvant chemotherapy plays important role in the survival outcome of majority of solid tumors.
Delaying adjuvant chemotherapy has been proven to worsen outcomes of many cancers, including colon and breast cancer, but unclear in EOC. Surgical resection leads to accelerated metastatic tumor growth due to shuttling of cells in G0 phase into the cell cycle. The interval between resection and chemotherapy provides opportunity for micrometastases to proliferate. But the impact of time to start adjuvant chemotherapy in EOC is unclear, even though multiple large retrospective data or meta-analysis exists in the literature. The impact of same after HIPEC has not been published so far.
Methods
Prospective study
Manipal Comprehensive Cancer Centre, Bangalore, India. METHODOLOGY:
Optimal cytoreduction done with standard steps of CRS.
In patients who were planned for intraperitoneal chemotherapy (IP), port was inserted at the end of the procedure. For patient who were planned for HIPEC, HIPEC was done by semi open technique at the end of CRS and was based on the institutional protocol (Inj cisplatin 100mg/m2 over 90min at 41.50. Patients received adjuvant chemotherapy on day-care basis after the recovery and IP chemotherapy for IP port group. Time to start adjuvant chemotherapy (from the day of surgery) was calculated for all 3 groups: 42 days was t ... 전체 초록 보기
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
Obstetrics & Gynecology Science
2021 .09
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in Stage IIIc Epithelial ovarian cancer and comparison of oncological outcome with cytoreductive surgery & intravenous chemotherapy & cytoreductive surgery plus normothermic port based intra-peritoneal chemotherapy
대한임상종양학회 학술대회지
2021 .06
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
Journal of Gynecologic Oncology
2022 .01
-
The Effect of Adjuvant Chemotherapy in the Elderly Patients Receiving Colorectal Cancer Surgeries: A Propensity Score-Matched Analysis
대한외과학회 학술대회 초록집
2021 .05
-
70세 이상의 노인 대장암 환자의 수술 후 보조요법의 위험 인자와 효과
Annals of geriatric medicine and research
2015 .01
-
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Cancer Research and Treatment
2023 .01
-
Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
Journal of Gynecologic Oncology
2015 .01
-
Indications and Effects of HIPEC
대한임상종양학회 학술대회지
2016 .02
-
Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2021 .06
-
Single Center Experience With Hyperthermic Intraperitoneal Chemotherapy
Annals of Coloproctology
2017 .01
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
Adjuvant Chemotherapy for Pancreatic Cancer
대한외과학회 학술대회 초록집
2022 .05
-
Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)
Journal of Gynecologic Oncology
2022 .07
-
Adjuvant chemotherapy in patients with stage II colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2021-514-001919798